Can you provide the consensus estimates for SECOND SIGHT MEDICAL PRODUCT next earnings?
The consensus EPS estimate for the next earnings of SECOND SIGHT MEDICAL PRODUCT (EYES) is -1.21 USD and the consensus revenue estimate is 2.81M USD.
SECOND SIGHT MEDICAL PRODUCT (EYES) Forecast, Price Target & Analyst Ratings
NASDAQ:EYES • US81362J3086
Current stock price
4.14 USD
-0.22 (-5.05%)
At close:
4.0921 USD
-0.05 (-1.16%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SECOND SIGHT MEDICAL PRODUCT (EYES).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- N/A
- Period
- Q4 / 2022
- EPS Estimate
- -$1.21
- Revenue Estimate
- 2.814M
Price Target Details & History
Consensus Price Target and Range
Mean target
$0.00
Upside
-100.00%
From current price of $4.14 to mean target of $0.00, Based on 7 analyst forecasts
Low
$0.00
Median
$0.00
High
$0.00
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.86%
EYES was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about EYES.
In the previous month the buy percentage consensus was at a similar level.
EYES was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
- Period
- Q4 / 2022
- EPS Estimate
- -$1.21
- Revenue Estimate
- 2.814M
- Revenue Q2Q
- N/A
- EPS Q2Q
- 15.00%
- Number of Analysts
- 3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates 2022 - 2024
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 7.964M 99.85% | 6.896M -13.41% | 3.379M -51.00% | 2.635M -100.00% | 2.073M | 2.814M | 6.93M 146.31% | 17.325M 150.00% | |
| EBITDA YoY % growth | -28.152M 14.11% | -34.19M -21.45% | -30.2M 11.67% | -30.874M 58.60% | -28.66M 29.11% | N/A | N/A | N/A | |
| EBIT YoY % growth | -28.609M 13.85% | -34.625M -21.03% | -30.597M 11.63% | -31.323M 58.60% | -29.133M 29.48% | N/A | N/A | N/A | |
| Operating Margin | -359.23% | -502.10% | -905.50% | -1,188.64% | -1,405.45% | N/A | N/A | N/A | |
| EPS YoY % growth | N/A -113.04% | N/A 5.45% | -6.54 48.62% | -8.39 87.00% | -10.58 -1,144.81% | -1.21 88.53% | -1.37 -13.07% | -1.37 |
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 22 | |
|---|---|
| EPS Q2Q % growth | -1.21 15.00% |
| Revenue Q2Q % growth | 2.814M |
| EBITDA Q2Q % growth | N/A |
| EBIT Q2Q % growth | N/A |
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
25.08%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
102.94%
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
SECOND SIGHT MEDICAL PRODUCT / EYES Forecast FAQ
What is the expected long term growth rate for SECOND SIGHT MEDICAL PRODUCT (EYES)?
The expected long term growth rate for SECOND SIGHT MEDICAL PRODUCT (EYES) is 102.94%.